A phase 3 study published in The Lancet reports that deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy, where there is no cure. In HOPE-3, participants receiving deramiocel showed slower declines in arm movement and elbow function versus placebo, with effects on cardiac function appearing in a subgroup of patients who already had heart muscle disease.